by IonsGate Preclinical Services | Feb 18, 2022 | Drug Discovery
Canada/Europe, 2 February 2022 – Canadian CRO IonsGate Preclinical Services Inc (IonsGate), that is a market leader in preclinical research services, and European life sciences company InSilicoTrials just announced a partnership to leverage innovative technology like...
by Linden Schwark | Feb 10, 2020 | Research
Feng Wei, Marc Pourrier, David G Strauss, Norman Stockbridge, Li Pang Published: 10 February 2020 Abstract Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold great potential for personalized cardiac safety prediction, particularly for that of...
by IonsGate Preclinical Services | Jan 21, 2020 | Research
By Marc Pourrier and David Fedida Published: 19 January 2020 Abstract: There is a need for improved in vitro models of inherited cardiac diseases to better understand basic cellular and molecular mechanisms and advance drug development. Most of these diseases are...
by IonsGate Preclinical Services | Oct 18, 2019 | Discover
If you’ve watched TV more than once in the past decade, you’ve probably heard something about artificial intelligence (AI). The prospect of human-like intelligence in machines has captivated our collective imagination since the first computers made their first...
by IonsGate Preclinical Services | Aug 27, 2019 | Discover
Safety and efficacy are two critical components of getting a new drug approved, however demonstrating these factors can be difficult in some classes of drugs. Medications that affect cardiac tissue require high scrutiny, as both their potential benefits and risks to...
by IonsGate Preclinical Services | Aug 19, 2019 | Discover
Safety assessments are a critical component of taking a potential pharmaceutical compound down the path from discovery to prescription drug. However, it is often difficult to assess whether a drug will affect everyone the same. Over the past few decades, doctors and...
by IonsGate Preclinical Services | Aug 16, 2019 | Research
Cellular models developed to better predict proarrhythmic liability of drug candidates include commercially-available human stem cell-derived cardiomyocytes (hiPSC-CM) obtained from healthy subjects. Cardiac safety assessment, however, should not be limited to...
by IonsGate Preclinical Services | Feb 7, 2019 | Research
Cellular models developed to better predict proarrhythmic liability of drug candidates include commercially-available human stem cell-derived cardiomyocytes (hiPSC-CM) obtained from healthy subjects. Cardiac safety assessment, however, should not be limited to...
by IonsGate Preclinical Services | Oct 6, 2016 | Research
If you missed Dr Pourrier’s presentation on the late sodium current (late INa) at the last SPS meeting in Vancouver (18-21 September 2016), you can download it here: Your Name (required) Your Email (required) [recaptcha]...
by IonsGate Preclinical Services | Nov 19, 2015 | Assays
Purkinje fiber assay It is well appreciated that acquired or drug induced-torsade de pointes (TdP), is associated with the generation of long action potential duration (APD)-related early after depolarizations (EADs) and EAD-induced triggered activity. EADs, occurring...
